We are live on ! Find out more
ZNTL icon

Zentalis Pharmaceuticals
ZNTL

86 hedge funds and large institutions have $54.9M invested in Zentalis Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 28 increasing their positions, 30 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% less repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 30

13% less funds holding

Funds holding: 99 → 86 (-13)

16.99% less ownership

Funds ownership: 73.17% → 56.18% (-17%)

31% less capital invested

Capital invested by funds: $79.7M → $54.9M (-$24.8M)

56% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 18

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
86
Holders Change
-13
Holders Change %
-13.13%
% of All Funds
1.05%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
8
Increased
28
Reduced
30
Closed
18
Calls
$27K
Puts
–
Net Calls
+$27K
Net Calls Change
+$74K

Top Buyers

Rank Fund Capital Flow
1
5VM
5AM Venture Management
California
+$5.03M
2
OM
Opaleye Management
Massachusetts
+$1.58M
3
Renaissance Technologies
Renaissance Technologies
New York
+$813K
4
Barclays
Barclays
United Kingdom
+$592K
5
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
+$591K

Top Sellers

Rank Fund Capital Flow
1
MCMC
Matrix Capital Management Company
New Hampshire
-$21.1M
2
TCM
Tang Capital Management
California
-$2.34M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$1.79M
4
Morgan Stanley
Morgan Stanley
New York
-$879K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$838K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jane Street
26
Jane Street
New York
$639K -$251K -172,448 -27%
SCM
27
Stonepine Capital Management
Oregon
$626K +$14.4K +9,900 +2%
PLC
28
Peapod Lane Capital
New York
$606K -$170K -116,510 -21%
BNP Paribas Financial Markets
29
BNP Paribas Financial Markets
France
$566K +$379K +260,432 +164%
State Street
30
State Street
Massachusetts
$367K – – –
Creative Planning
31
Creative Planning
Kansas
$351K – – –
Marshall Wace
32
Marshall Wace
United Kingdom
$335K +$361K +247,788 New
Fidelity Investments
33
Fidelity Investments
Massachusetts
$328K +$58.2K +40,003 +20%
ACM
34
Anfield Capital Management
California
$328K +$249K +171,228 +240%
Invesco
35
Invesco
Georgia
$255K +$21.8K +14,961 +9%
JP Morgan Chase
36
JP Morgan Chase
New York
$250K -$783K -538,068 -74%
Wealth Enhancement Advisory Services
37
Wealth Enhancement Advisory Services
Minnesota
$232K -$52.2K -35,883 -22%
SEI Investments
38
SEI Investments
Pennsylvania
$226K – – –
QC
39
Quadrature Capital
United Kingdom
$186K +$112K +76,917 +127%
QL
40
Quarry LP
New York
$178K +$33.8K +23,250 +21%
OC
41
Opal Capital
Florida
$173K +$105K +72,251 New
Jacobs Levy Equity Management
42
Jacobs Levy Equity Management
New Jersey
$168K -$838K -576,051 -82%
Goldman Sachs
43
Goldman Sachs
New York
$160K -$330K -226,943 -66%
Walleye Capital
44
Walleye Capital
New York
$149K -$14.6K -10,000 -8%
Squarepoint
45
Squarepoint
New York
$145K +$126K +86,412 +405%
Point72 Asset Management
46
Point72 Asset Management
Connecticut
$135K +$146K +100,290 New
Dimensional Fund Advisors
47
Dimensional Fund Advisors
Texas
$130K -$129K -88,769 -48%
Northern Trust
48
Northern Trust
Illinois
$125K -$1.82K -1,248 -1%
GCM
49
Graham Capital Management
Connecticut
$123K -$89.1K -61,237 -40%
PAM
50
Panagora Asset Management
Massachusetts
$117K -$16.4K -11,258 -11%
1
2
3 4 5

ZNTL Hedge Fund Activity: Q4 2025 in Review

86 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q4 2025, worth a combined $54.9M — down 31% from $79.7M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of ZNTL and 8 opened new positions — a net loss of 10 holders — while 30 trimmed existing stakes and 28 added.

The largest buyer was 5AM Venture Management, adding an estimated $5.03M. The largest seller was Matrix Capital Management Company, exiting entirely with an estimated $21.1M sold.

  • 86 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q4 2025, down from 99 in Q3 2025.
  • Funds reported $54.9M of Zentalis Pharmaceuticals stock for Q4 2025, down 31% quarter-over-quarter.
  • 8 funds opened new Zentalis Pharmaceuticals positions in Q4 2025 and 18 closed out, a net change of -10 holders.
  • The largest Zentalis Pharmaceuticals buyer in Q4 2025 was 5AM Venture Management, an estimated $5.03M added.
  • The largest Zentalis Pharmaceuticals seller in Q4 2025 was Matrix Capital Management Company, an estimated $21.1M sold.

Based on aggregated 13F filings for Q4 2025.